PDS Biotechnology Reports $7.3 Million Net Loss in Q1 2026, Focuses on Clinical Pipeline

PDS Biotechnology Corporation reported a net loss of $7.3 million for the first quarter of 2026, a decrease from the $8.5 million loss recorded in the same period of 2025. The company's total operating expenses fell to $6.5 million, down 28% from $9.1 million year-over-year, primarily due to a significant reduction in research and development costs, which decreased by 41% to $3.5 million. General and administrative expenses also saw a slight decline, totaling $3.1 million compared to $3.3 million in the previous year. The decrease in expenses reflects the company's ongoing efforts to manage costs while advancing its clinical programs.

As of March 31, 2026, PDS Biotechnology's cash and cash equivalents stood at $21.7 million, down from $26.7 million at the end of 2025. The company has not generated any revenue from product sales and continues to rely on financing activities to support its operations. During the first quarter, PDS raised approximately $0.85 million through the sale of 937,420 shares of common stock under its at-the-market offering program. This is a notable increase compared to the $0.3 million raised from the sale of 205,350 shares in the same period last year.

Strategically, PDS Biotechnology is focused on advancing its clinical pipeline, which includes the Versamune® platform and the PDS01ADC investigational product. The company is currently conducting several clinical trials, including the VERSATILE-003 Phase 3 trial for PDS0101 in HPV16-positive head and neck cancer. Recent developments include the adoption of an amended protocol for this trial, which now incorporates progression-free survival as a primary endpoint for interim analysis. The company is also exploring partnerships and collaborations to enhance its research and development capabilities.

Operationally, PDS Biotechnology has experienced changes in its employee headcount, reflecting its focus on optimizing resources. The company continues to face challenges related to its liquidity and capital resources, as it has incurred net losses since inception and anticipates ongoing operating losses. The company has indicated that it may need to raise additional capital through equity or debt financing to support its clinical development efforts and meet its operational needs. The outlook remains cautious, with substantial doubt about the company's ability to continue as a going concern for at least the next 12 months, pending successful capital raising efforts.